Oculis (NASDAQ:OCS) Coverage Initiated by Analysts at Needham & Company LLC

Needham & Company LLC began coverage on shares of Oculis (NASDAQ:OCSFree Report) in a research report report published on Wednesday morning, Marketbeat.com reports. The firm issued a buy rating and a $36.00 target price on the stock.

Other research analysts also recently issued reports about the stock. HC Wainwright upped their price target on shares of Oculis from $32.00 to $33.00 and gave the stock a “buy” rating in a report on Friday, August 22nd. Chardan Capital boosted their price objective on Oculis from $28.00 to $33.00 and gave the stock a “buy” rating in a research report on Friday, May 9th. Four investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus price target of $35.75.

View Our Latest Stock Report on OCS

Oculis Stock Down 1.1%

OCS stock opened at $17.33 on Wednesday. The firm has a 50-day moving average price of $18.27 and a 200-day moving average price of $18.61. Oculis has a 12 month low of $11.56 and a 12 month high of $23.08. The company has a current ratio of 4.55, a quick ratio of 4.55 and a debt-to-equity ratio of 0.01. The stock has a market capitalization of $756.63 million, a P/E ratio of -6.49 and a beta of 0.27.

Oculis (NASDAQ:OCSGet Free Report) last announced its quarterly earnings results on Thursday, August 21st. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.06). The company had revenue of $0.25 million for the quarter, compared to the consensus estimate of $0.14 million. Oculis had a negative net margin of 13,958.12% and a negative return on equity of 90.31%. As a group, equities research analysts anticipate that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Investors Weigh In On Oculis

Institutional investors have recently modified their holdings of the company. Bellevue Group AG acquired a new stake in shares of Oculis during the fourth quarter worth $170,000. Kestra Private Wealth Services LLC acquired a new position in Oculis in the first quarter valued at $234,000. Geode Capital Management LLC boosted its position in Oculis by 12.0% during the fourth quarter. Geode Capital Management LLC now owns 16,744 shares of the company’s stock valued at $284,000 after acquiring an additional 1,800 shares during the last quarter. Bosun Asset Management LLC acquired a new stake in Oculis during the 2nd quarter worth about $378,000. Finally, Citadel Advisors LLC acquired a new stake in Oculis during the 4th quarter worth about $389,000. 22.30% of the stock is owned by institutional investors.

Oculis Company Profile

(Get Free Report)

Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis.

Further Reading

Receive News & Ratings for Oculis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oculis and related companies with MarketBeat.com's FREE daily email newsletter.